Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala 695014, India.
Biomed Res Int. 2013;2013:517237. doi: 10.1155/2013/517237. Epub 2013 Nov 4.
Classically, isolation of CSCs from tumors exploits the detection of cell surface markers associated with normal stem cells. Invariable expression of these cell surface markers in almost all proliferating tumor cells that albeit impart specific functionality, the universality, and clinical credibility of CSC phenotype based on markers is still dubious. Side Population (SP) cells, as defined by Hoechst dye exclusion in flow cytometry, have been identified in many solid tumors and cell lines and the SP phenotype can be considered as an enriched source of stem cells as well as an alternative source for the isolation of cancer stem cells especially when molecular markers for stem cells are unknown. SP cells may be responsible for the maintenance and propagation of tumors and the proportion of SP cells may be a predictor of patient outcome. Several of these markers used in cell sorting have emerged as prognostic markers of disease progression though it is seen that the development of new CSC-targeted strategies is often hindered by poor understanding of their regulatory networks and functions. This review intends to appraise the experimental progress towards enhanced isolation and drug screening based on property of acquired chemoresistance of cancer stem cells.
传统上,从肿瘤中分离 CSCs 利用了与正常干细胞相关的细胞表面标志物的检测。这些细胞表面标志物在几乎所有增殖的肿瘤细胞中不变的表达,尽管赋予了特定的功能,但基于标志物的 CSC 表型的普遍性和临床可信度仍然值得怀疑。侧群 (SP) 细胞,如流式细胞术中海因斯染色排除所定义的,已经在许多实体瘤和细胞系中被发现,SP 表型可以被认为是干细胞的丰富来源,也是分离癌症干细胞的替代来源,特别是当干细胞的分子标志物未知时。SP 细胞可能负责肿瘤的维持和增殖,SP 细胞的比例可能是患者预后的预测指标。尽管人们发现,新的 CSC 靶向策略的发展往往受到对其调节网络和功能的理解不足的阻碍,但在细胞分选中使用的一些标记物已经成为疾病进展的预后标志物。这篇综述旨在评估基于癌症干细胞获得性耐药性特性的增强分离和药物筛选的实验进展。